Clinical Trials Browser

NETWORK × Recurrence × elotuzumab × Clear all

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Phase 1/2 Terminated

Multiple Myeloma, Recurrence